Abstract: Rationale: This study reports the first case of congenital hypothyroidism (CH) and alpha thalassemia in a child in China, with anemia and muscle damage as the main manifestations. Analyzing and studying this case is of great significance in reducing missed and misdiagnosed CH and will provide a clinical strategy for treating these patients.
Patient Concerns: Child, female, 2 years and 7 months old, the child appeared dispirited, had poor appetite, shallow complexion, reduced activities with anemia, elevated muscle enzymes, height, and growth retardation.
Diagnoses: The child was diagnosed with CH with alpha thalassemia.
Interventions: The patient was treated with levothyroxine sodium and anemia correction.
Outcomes: The children's current spirit, appetite, red face, normal limb activity, physical development, and intelligence were significantly better than those of normal children of the same age.
Conclusions: CH with alpha thalassemia, especially anemia and muscle damage as the main manifestations, has not been reported. Administration of levothyroxine sodium is effective in correcting anemia in patients with CH and alpha thalassemia.
Lesson: Due to CH and alpha thalassemia, there are no specific symptoms and they are prone to missed diagnosis and misdiagnosis. Therefore, patients with anemia and elevated muscle enzyme levels should be routinely tested for thyroid function to diagnose them early and provide proper treatment to avoid negative consequences.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Kollati Y, Ambati RR, Reddy PN, Kumar NSS, Patel RK, Dirisala VR. Congenital hypothyroidism: facts, facets & therapy. Curr Pharm Des. 2017;23:2308–13.
Wassner AJ. Congenital hypothyroidism. Clin Perinatol. 2018;45:1–18.
Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of β-thalassemia. Eur J Haematol. 2020;105:692–703.
Mensah C, Sheth S. Optimal strategies for carrier screening and prenatal diagnosis of alpha- and beta-thalassemia. Hematology Am Soc Hematol Educ Program. 2021;2021:607–13.
Musallam KM, Lombard L, Kistler KD, et al. Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps. Am J Hematol. 2023;98:1436–51.
Chong SC, Metassan S, Yusof N, et al. Thalassemia in Asia 2021 Thalassemia in Brunei Darussalam. Hemoglobin. 2022;46:15–9.
Wang WD, Hu F, Zhou DH, et al. Thalassaemia in China. Blood Rev. 2023;60:101074.
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–6.
Farashi S, Harteveld CL. Molecular basis of alpha-thalassemia. Blood Cells Mol Dis. 2018;70:43–53.
Zhong YH, Ye LX, Cai XJ, Xie CL, Chen JG. Gene characteristics and changing trend of neonatal thalassemia in Dongguan, China. Zhongguo Dang Dai Er Ke Za Zhi. 2020;22:454–9.
Ng YY, Lin HD, Wu SC, et al. Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients. Thyroid. 2013;23:552–61.
Wu YC, Wu YH, Wang YP, Chang JY, Chen HM, Sun A. Antigastric parietal cell and antithyroid autoantibodies in patients with recurrent aphthous stomatitis. J Formos Med Assoc. 2017;116:4–9.
Wiersinga WM, Touber JL. The relation between gastrin, gastric acid and thyroid function disorders. Acta Endocrinol (Copenh). 1980;95:341–9.
Lugovaya LA, Necrasova TA, Strongin LG, Belyaeva NG. Compensated hypothyroidism and statin administration: the symptoms of muscle damage and muscle metabolism disorders. Probl Endokrinol (Mosk). 2020;65:408–16.
Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J. 2017;13:55–9.
Wolffenbuttel BHR, Wouters H, Slagter SN, et al. Thyroid function and metabolic syndrome in the population-based LifeLines cohort study. BMC Endocr Disord. 2017;17:65.
Processing Request
No Comments.